EL7.AI
StocksMedium•28 October 2026•
2 min read

Replimune’s fiscal second-quarter loss of $0.54 per share beats estimates by $0.21

Key Facts

1GAAP loss per share was $0.54, beating estimates by $0.21.
2REPL closed at $13.05 on October 27, 2026.
3Net loss was $69.8 million in the first fiscal quarter of 2027, compared with $86.7 million in the year-earlier period.
4Proceeds from the share offering totaled $141.0 million in August, and the company said liquidity was sufficient to fund operations for more than 12 months.

Replimune posted a GAAP loss per share of $0.54 in the fiscal second quarter of 2027, according to a headline published by Seeking Alpha on October 28. The headline said the loss was $0.21 better than analysts’ estimate. The fiscal period ended September 30, 2026, according to the results statement the company issued on October 28. That places the figure in the fiscal second quarter, not the third quarter as stated in the earlier version of the story. The company’s shares, listed under the ticker REPL, closed at $13.05 on October 27, according to EL7 data.

Results for the first fiscal quarter of 2027, ended June 30, 2026, showed a net loss of $69.8 million, compared with $86.7 million in the same period a year earlier, the company said. In that quarter, cash and cash equivalents and short-term investments totaled $195.3 million as of June 30, compared with $268.9 million as of March 31. The company said net proceeds from its August share offering totaled $141.0 million, and that available liquidity was expected to fund operations for more than 12 months from the date of the first-quarter results. In an earlier update, it said the Phase 3 IGNYTE-3 trial evaluating RP1 with nivolumab versus investigator’s choice was actively enrolling participants, with overall survival as the primary endpoint and a readout expected in 2030. On August 6, the company announced the FDA’s accelerated approval of TUDRIQEV with nivolumab for adults with advanced unresectable melanoma whose disease progressed after a PD-1 antibody-based regimen.

The company had scheduled its fiscal second-quarter results call for October 28, 2026, at 8:00 a.m. Eastern time, according to its investor relations website. The call comes on the day it reports financial results for the period ended September 30. Investors are also tracking the IGNYTE-3 trial, for which the company expects a readout on its primary endpoint in 2030. The company previously announced accelerated approval of TUDRIQEV in August. The shares closed at $13.05 on the day before the results announcement, according to EL7 data.

Open on chart